|
US20030157064A1
(en)
*
|
2001-11-09 |
2003-08-21 |
Pascal Neuville |
Chimeric promoters for controlling expression in muscle cells
|
|
US20080044393A1
(en)
*
|
2004-07-16 |
2008-02-21 |
White Robert L |
Retinal dystrophin transgene and methods of use thereof
|
|
US8557969B2
(en)
|
2004-12-01 |
2013-10-15 |
The Regents Of The University Of Michigan |
Compositions and methods for regulating cardiac performance
|
|
US8383601B2
(en)
*
|
2006-10-30 |
2013-02-26 |
Thomas Jefferson University |
Tissue specific gene therapy treatment
|
|
US20120322861A1
(en)
|
2007-02-23 |
2012-12-20 |
Barry John Byrne |
Compositions and Methods for Treating Diseases
|
|
CA2834729A1
(en)
|
2011-04-06 |
2012-10-11 |
Universite Pierre Et Marie Curie (Paris 6) |
A skeletal muscle-specific enhancer
|
|
EP3818991A3
(en)
|
2012-06-19 |
2021-07-14 |
University of Florida Research Foundation, Inc. |
Compositions and methods for treating diseases
|
|
US9845465B2
(en)
|
2012-08-15 |
2017-12-19 |
University Of Virginia Patent Foundation |
Compositions and methods for treating peripheral arterial disease
|
|
AU2013364158A1
(en)
|
2012-12-20 |
2015-07-09 |
Sarepta Therapeutics, Inc. |
Improved exon skipping compositions for treating muscular dystrophy
|
|
HRP20190382T1
(hr)
|
2013-03-14 |
2019-04-19 |
Sarepta Therapeutics, Inc. |
Pripravci koji preskaču ekson za liječenje mišićne distrofije
|
|
BR112015023001B8
(pt)
|
2013-03-14 |
2022-08-09 |
Sarepta Therapeutics Inc |
Oligonucleotídeo antisenso, composição farmacêutica compreendendo o mesmo e uso da dita composição para o tratamento de distrofia muscular de duchenne (dmd)
|
|
US20160220647A1
(en)
*
|
2013-09-09 |
2016-08-04 |
University Of Washington Through Its Center For Commercialization |
Proteins for targeting neuronal nitric oxide synthase to muscle sarcolemma and related methods of use
|
|
EP3800261A1
(en)
*
|
2014-01-21 |
2021-04-07 |
Vrije Universiteit Brussel |
Muscle-specific nucleic acid regulatory elements and methods and use thereof
|
|
WO2016139354A1
(de)
|
2015-03-05 |
2016-09-09 |
Peter Und Traudl Engelhorn-Stiftung Zur Förderung Der Lebenswissenschaften |
System zur präsentation von peptiden auf der zelloberfläche
|
|
GB201508025D0
(en)
|
2015-05-11 |
2015-06-24 |
Ucl Business Plc |
Fabry disease gene therapy
|
|
CN104894651B
(zh)
*
|
2015-06-29 |
2017-04-12 |
天津诺禾医学检验所有限公司 |
微量起始dna的高通量测序文库构建方法及其所构建的高通量测序文库
|
|
EP3350331A4
(en)
*
|
2015-09-17 |
2019-01-23 |
Research Institute at Nationwide Children's Hospital |
METHOD AND MATERIALS FOR GALGT2 GENE THERAPY
|
|
SG11201808981XA
(en)
|
2016-04-14 |
2018-11-29 |
Benitec Biopharma Ltd |
Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof
|
|
US11202840B2
(en)
|
2016-06-21 |
2021-12-21 |
The Curators Of The University Of Missouri |
Modified dystrophin proteins
|
|
TWI722310B
(zh)
|
2017-08-03 |
2021-03-21 |
美商航海家醫療公司 |
用於aav之遞送之組合物及方法
|
|
AU2018352236B2
(en)
|
2017-10-16 |
2025-04-10 |
The Curators Of The University Of Missouri |
Treatment of amyotrophic lateral sclerosis (ALS)
|
|
WO2019079242A1
(en)
|
2017-10-16 |
2019-04-25 |
Voyager Therapeutics, Inc. |
TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
|
|
US12296026B2
(en)
|
2018-02-05 |
2025-05-13 |
Astellas Gene Therapies, Inc. |
Transcription regulatory elements and uses thereof
|
|
JP7467356B2
(ja)
|
2018-02-07 |
2024-04-15 |
ジェネトン |
ハイブリッド調節要素
|
|
US12129476B2
(en)
|
2018-04-27 |
2024-10-29 |
Voyager Therapeutics, Inc. |
Methods for measuring the potency of AADC viral vectors
|
|
US12319929B2
(en)
|
2018-05-15 |
2025-06-03 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of Parkinson's disease
|
|
US20210230632A1
(en)
|
2018-05-15 |
2021-07-29 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
US12060567B2
(en)
|
2018-06-13 |
2024-08-13 |
Voyager Therapeutics, Inc. |
Engineered untranslated regions (UTR) for AAV production
|
|
CN112567035A
(zh)
|
2018-07-02 |
2021-03-26 |
沃雅戈治疗公司 |
肌萎缩侧索硬化症及脊髓相关病症的治疗
|
|
US20210348242A1
(en)
|
2018-10-04 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Methods for measuring the titer and potency of viral vector particles
|
|
US20210348194A1
(en)
|
2018-10-05 |
2021-11-11 |
Voyager Therapeutics, Inc. |
Engineered nucleic acid constructs encoding aav production proteins
|
|
WO2020077165A1
(en)
|
2018-10-12 |
2020-04-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for delivery of aav
|
|
JP2022505106A
(ja)
|
2018-10-15 |
2022-01-14 |
ボイジャー セラピューティクス インコーポレイテッド |
バキュロウイルス／Ｓｆ９システムにおけるｒＡＡＶの大規模産生のための発現ベクター
|
|
BR112021009481A2
(pt)
|
2018-11-16 |
2021-08-17 |
Astellas Pharma Inc. |
método para tratamento da distrofia muscular direcionando gene de utrofina.
|
|
WO2020150556A1
(en)
|
2019-01-18 |
2020-07-23 |
Voyager Therapeutics, Inc. |
Methods and systems for producing aav particles
|
|
SG11202108469XA
(en)
|
2019-02-28 |
2021-09-29 |
Benitec Ip Holdings Inc |
Compositions and methods for treating oculopharyngeal muscular dystrophy (opmd)
|
|
EP3952920A1
(en)
*
|
2019-04-08 |
2022-02-16 |
Genethon |
Hybrid promoters for muscle expression
|
|
WO2020227515A1
(en)
|
2019-05-07 |
2020-11-12 |
Voyager Therapeutics, Inc. |
Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation
|
|
EP3976785A1
(en)
|
2019-05-28 |
2022-04-06 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting dmpk gene
|
|
AU2020334462A1
(en)
|
2019-08-16 |
2022-02-24 |
Modalis Therapeutics Corporation |
Method for treating muscular dystrophy by targeting LAMA1 gene
|
|
WO2021046155A1
(en)
|
2019-09-03 |
2021-03-11 |
Voyager Therapeutics, Inc. |
Vectorized editing of nucleic acids to correct overt mutations
|
|
EP4126910A1
(en)
|
2020-04-01 |
2023-02-08 |
Voyager Therapeutics, Inc. |
Redirection of tropism of aav capsids
|
|
EP4135841A1
(en)
|
2020-04-15 |
2023-02-22 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
KR20230022175A
(ko)
|
2020-05-13 |
2023-02-14 |
보이저 테라퓨틱스, 인크. |
Aav 캡시드의 향성 방향변경
|
|
WO2021230385A1
(en)
|
2020-05-15 |
2021-11-18 |
Astellas Pharma Inc. |
Method for treating muscular dystrophy by targeting utrophin gene
|
|
WO2021247995A2
(en)
|
2020-06-04 |
2021-12-09 |
Voyager Therapeutics, Inc. |
Compositions and methods of treating neuropathic pain
|
|
CA3192120A1
(en)
*
|
2020-09-11 |
2022-03-17 |
James A. Williams |
Muscle-specific hybrid promoter
|
|
US20220098615A1
(en)
|
2020-09-30 |
2022-03-31 |
NGGT, Inc. |
Dual functional expression vectors and methods of use thereof
|
|
JP2023548746A
(ja)
|
2020-10-13 |
2023-11-21 |
クリヤ セラピューティクス インコーポレイテッド |
サイトカインをコードする核酸を送達するためのウイルスベクターコンストラクトおよびがんを処置するためのその使用
|
|
AR124143A1
(es)
|
2020-11-25 |
2023-02-15 |
Astellas Pharma Inc |
Método para tratar la distrofia muscular mediante el direccionamiento al gen dmpk
|
|
AU2022214822A1
(en)
|
2021-01-26 |
2023-08-17 |
Kriya Therapeutics, Inc. |
Vector constructs for delivery of nucleic acids encoding therapeutic anti-tnf antibodies and methods of using the same
|
|
EP4036238A1
(en)
*
|
2021-01-27 |
2022-08-03 |
The University Court of the University of Edinburgh |
Functional nucleic acid molecule and method
|
|
WO2022174113A1
(en)
|
2021-02-12 |
2022-08-18 |
Merand Pharmaceuticals, Inc. |
Agents, compositions, and methods for the treatment of hypoxia and ischemia-related disorders
|
|
US20240141383A1
(en)
|
2021-03-04 |
2024-05-02 |
Kriya Therapeutics, Inc. |
Viral vector constructs incorporating dna for inhibiting toll like receptors and methods of using the same
|
|
CA3226119A1
(en)
*
|
2021-08-04 |
2023-02-09 |
Giuseppe RONZITTI |
Hybrid promoters for gene expression in muscles and in the cns
|
|
WO2023023055A1
(en)
|
2021-08-16 |
2023-02-23 |
Renagade Therapeutics Management Inc. |
Compositions and methods for optimizing tropism of delivery systems for rna
|
|
JP2024534697A
(ja)
|
2021-09-14 |
2024-09-20 |
レナゲード セラピューティクス マネージメント インコーポレイテッド |
非環状脂質及びその使用方法
|
|
CA3232386A1
(en)
|
2021-09-14 |
2023-03-23 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and methods of use thereof
|
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
JP2025503637A
(ja)
|
2022-01-09 |
2025-02-04 |
クリヤ セラピューティクス， インコーポレイテッド |
治療用抗ｉｇｆ－１ｒ抗体をコードする核酸の送達のためのベクター構築物およびそれを使用する方法
|
|
CN118829729A
(zh)
*
|
2022-03-16 |
2024-10-22 |
罗格斯新泽西州立大学 |
受控的肌肉特异性基因递送
|
|
AU2023251104A1
(en)
|
2022-04-07 |
2024-10-17 |
Renagade Therapeutics Management Inc. |
Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents
|
|
US20250295809A1
(en)
|
2022-05-13 |
2025-09-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
|
EP4543473A1
(en)
|
2022-06-22 |
2025-04-30 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
|
JP2025526502A
(ja)
*
|
2022-07-11 |
2025-08-13 |
ヴァイタ セラピューティクス， インコーポレイテッド |
筋ジストロフィーを処置するための治療用サテライト細胞の製造
|
|
JP2025535203A
(ja)
|
2022-09-15 |
2025-10-23 |
ボイジャー セラピューティクス インコーポレイテッド |
タウ結合化合物
|
|
WO2025014832A1
(en)
|
2023-07-07 |
2025-01-16 |
Kriya Therapeutics, Inc. |
Periocular delivery of aav vectors for treating ophthalmic pathologies
|